ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck 1Q Net Rises 67% On Lower Costs; Sales Growth Slows

DOW JONES NEWSWIRES Merck & Co.'s (MRK) first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth. Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin. Merck has said it expects to seek regulatory approval for five new products this year and in 2013, including potential treatments for osteoporosis, insomnia and a next-generation vaccine against a cancer-causing virus. The drug maker also has been focusing on areas such as hepatitis C and diabetes. Merck reported a profit of $1.74 billion, or 56 cents a share, up from $1.04 billion, or 34 cents, a year earlier. Excluding items such as acquisition-related and restructuring costs, earnings rose to 99 cents from 92 cents. Its March projection was earnings of 95 cents to 98 cents a share, below analysts' expectations at the time. Sales rose 1.3% to $11.73 billion, missing the $11.82 billion forecast from analysts polled by Thomson Reuters. Operating margin rose to 21.4% from 14.9%, reflecting a 14% drop in research and development costs. Pharmaceutical sales grew 2.7% to $10.08 billion. Singulair sales edged up 0.9%, while sales of Vytorin declined 8%. The animal-health business, which includes products for farm animals and pets, posted a 8.3% revenue increase. Sales in the consumer division--which includes over-the-counter allergy medicine Claritin and Coppertone skin-care products--rose 7.2%. Shares closed Thursday at $38.47 and were inactive premarket. The stock is up 2% so far this year. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
04/19/201512:45:00Présentation au congrès annuel de l'AACR des résultats préliminaires de...
04/19/201512:45:00Early Findings with Pembrolizumab, Merck's Investigational Anti-PD-1...
04/19/201509:26:48Merck's Keytruda Shows Improved Survival Odds for Melanoma Patients
04/19/201508:30:00Présentation au congrès annuel de l'AACR et publication dans l...
04/19/201508:30:00Le pembrolizumab, le traitement anti-PD-1 expérimental de Merck...
04/19/201508:30:00Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with...
04/19/201508:30:00Pembrolizumab, Merck's Investigational anti PD-1 Therapy, Demonstrates...
04/18/201515:02:033 Drug Stocks Leading the Charge Against Infectious Diseases
04/18/201510:02:03What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
04/16/201508:03:02The Best Stock to Invest in Hep C
04/14/201513:30:00Phase III Trial of the Merck and NewLink Genetics Investigational...
04/14/201509:20:21Heat Biologics Is An Opportunity Among Soaring Immunotherapy...
04/14/201508:44:32The Growing Business Of Animal Healthcare
04/14/201507:00:00NewLink Genetics and Merck & Co Receives Vaccine Industry Excellence...
04/13/201521:12:18The New Dogs Of The Dow - Q1 2015
04/13/201518:02:26Merck CEO's 2014 Total Compensation Valued at $25 Million...
04/13/201517:26:06Statement of Changes in Beneficial Ownership (4)
04/13/201516:34:12Additional Proxy Soliciting Materials (definitive) (defa14a)
04/13/201516:33:18Proxy Statement (definitive) (def 14a)
04/13/201513:40:09Fitch Downgrades Merck

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad